Scientific, Medical Luminaries Gather At New York Symposium To Discuss The Science Of Electroceuticals

An impressive lineup of medical researchers and clinicians, including Nobel Laureate Louis Ignarro, PhD, gathered at a December 19 symposium in New York City to discuss the new and important scientific discipline of Electroceuticals. В В The next frontier in pulsed electromagnetic field (PEMF) therapy and electrotherapeutics, Electroceuticals are highly-refined electromagnetic fields that are now being used to non-invasively "jumpstart" the body's natural anti-inflammatory response to treat pain successfully and help soft tissue wounds heal faster.В 

В  Speakers discussed how advances in physics, biology and engineering have all begun to allow medical clinicians to directly affect the electrochemical processes that control all biological processes.В  The complete proceedings, which are summarized below, can be accessed at http://www.ivivitechnologies.com.

В В  "The science of Electroceuticals is so rich; it is always thrilling to bring such incredible minds together to discuss this exciting field," said Andre DiMino, founder and Co-CEO of Ivivi Technologies, Inc., a company dedicated to the field of electrotherapeutics and sponsor of the symposium.

В  DiMino introduced the symposium line-up.В  Some key presenters and panelists included:

В  Arthur Pilla, PhD., the original developer of bone growth stimulation technology and a leading authority on bioelectromagnetic responses in therapeutic medical applications provided a "state of the science" and discussed the creation and identification of electrotherapeutic signals.В 

В  Pilla, a professor of biomedical engineering at Columbia University, said that applications for which Electroceuticals are already known to be effective include the healing of recalcitrant bone fractures, increasing the success rate of spinal fusion from 50% to 85%, healing chronic and acute soft tissue wounds, suppressing the body's inflammatory response, increasing local blood circulation, and perhaps most exciting, encouraging angiogenesis.

В  Pilla also discussed the practical effects of electrotheraputic technologies вЂ" namely reducing costs of healthcare by reducing surgery and morbidity.В  In 1980, bone growth stimulators reduced the cost of health care for delayed union fractures by tenfold. In fact, recent studies have shown Electroceuticals' tremendous promise to significantly reduce healing time, including 59% on surgical wounds, 69% on tendons and 70% on chronic wounds, such as diabetic foot ulcers. В 

В  Pilla then took attendees across the evolution of the technology to today's Electroceuticals which activate the Calcium(Ca)-Calmodulin(CaM)-Nitric Oxide(NO) pathways that are at the core of the body's healing cascade.

В  Louis Ignarro, PhD., who received the 1998 Nobel Prize in Medicine and Physiology for his seminal work on the biological importance of nitric oxide, gave a presentation on the link between Nitric Oxide (NO) and the biological cascade stimulated by the application of Electroceuticals.

В  Ignarro, a professor of pharmacology at UCLA, began by discussing the discovery of biological importance of NO, its pharmacological uses, and his discovery that arteries produce NO that maintains the health of the vasculature.В  One well-known outcome is the discovery that NO was the neurotransmitter that stimulated male erections, leading to the development of Viagra.В 

В  Ignarro's research has discovered that NO has a multitude of functions in the body, helping to regulate processes that include angiogenesis, blood pressure control, digestion, respiration and promotion of learning and memory.В  NO, found naturally in the human body, is potentially analgesic, anti-oxidant and anti-inflammatory, depending on the biological circumstances.

В  Dr. Ignarro described how Ca/CaM activates the enzymes responsible for healthy NO production, the precise binding mechanism triggered by Electroceuticals.В 

В  Diana Casper, PhD., is a neurobiologist at the Albert Einstein School of Medicine, specializing in neurodegeneration.В  She runs the neurosurgery lab at the Montefiore Medical Center. В В 

В  Casper gave a short history of Parkinson's disease, including pathology and treatments.В  She highlighted a 2003 study that determined Parkinson's may be related to inflammation of brain cells, which lasts until death.В  Having learned about the effects of pulsed electromagnetic fields, Casper became interested in the possibility that PEMF may help increase neuronal survival in response to inflammation.

В  While Casper's research is ongoing, she showed preliminary data which demonstrated the promise of PEMF on neurodegenerative diseases.В  Cultures treated with PEMF demonstrated improved neuronal survival.В  She also presented data demonstrating decreases in acute inflammation after brain trauma, potentially promising work for problems of inflammation associate with brain trauma.В  In a third study, Casper's lab demonstrated that PEMF increases NO levels, which, in turn, has neuroprotective properties.В 

В  Casper proposed next steps involve animal studies using models of neurodegenerative diseases.В  Among the possible neuronal applications for PEMF treatments are Parkinson's, Alzheimer's, Huntington's disease.

В  In addition to the keynote speakers, attendees and panelists included several practicing clinicians who described their successful experiences using Electroceuticals to treat patients.В  One clinician described his ongoing study of the effect of Electroceuticals on heart disease, based on the known effects of Electroceuticals in improving angiogenesis.

В  To access the complete Symposium proceedings please log on to http://www.ivivitechnolgies.com.

В  About Ivivi Technologies:

Ivivi Technologies, Inc. (AMEX: II) is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform.В  Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation.В  Since the mid-1990's, the Company's Electroceuticals™ have been used for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

В  Forward-Looking Statements:

This press release contains "forward looking statements" that are subject to risk and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's registration statement on Form SB-2.В  These risks could cause actual results to differ materially from those expressed in any forward looking statements made by, or on behalf of, the Company.В  The Company assumes no obligation to update the information contained in this press release.